- Jan 22, 2021

FDA Approves Crizotinib for Pediatric ALK+ ALCL Indication

Crizotinib—a tyrosine kinase inhibitor with activity against ALK, ROS1, and MET—was granted FDA approval for use in pediatric patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma.

World-first guidelines created to prevent heart complications in children during cancer treatment

Patient Activated Education Effective as Surveillance for Skin Cancer in Childhood Cancer Survivors

Childhood, Adolescent Cancers Linked to Higher Risk of Major Psychiatric Disorders

Low BMD, fracture risk upped in childhood cancer survivors

Understanding How Childhood Brain Tumors Develop

American Academy of Pediatrics Issues New Recommendations on Hospitalized Adolescents

Genes that cause rare hidden cancer revealed

Stopping a rare childhood cancer in its tracks

Pediatric Cancer Vaccine May Be ‘Too Good to Be True,’ But More Work Is Needed

New research identifies a potential treatment target for hepatoblastoma in children

Recent Posts

FDA Approves Crizotinib for Pediatric ALK+ ALCL Indication

Archive

Search By Tags